Log in

Relevant bibliographies by topics / TMPRSS2-ERG fusion

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'TMPRSS2-ERG fusion'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'TMPRSS2-ERG fusion.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "TMPRSS2-ERG fusion"

1

He, Wei, Fukang Sun, Juping Zhao, et al. "Prevalence and genetic features of TMPRSS2-ERG fusion in Chinese patients with prostate cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): e17529-e17529. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e17529.

Full text

Abstract:

e17529 Background: Prostate cancer (PCa) is one of the most common malignancies, with rising incidence rate in China. The Cancer Genome Atlas (TCGA) revealed 53% of patients with PCa had ETS family gene fusions. The most frequent fusion type of ETS fusions is TMPRSS2-ERG, which may predicts resistance to taxane and androgen-deprivation therapies. The prevalence of TMPRSS2-ERG fusion in Chinese PCa patients evaluated by fluorescence in situ hybridization (FISH) or immunohistochemistry (IHC) varied from 7.5% to 78.0%. However, the sample sizes were small. In the present study, we investigated th

APA, Harvard, Vancouver, ISO, and other styles

2

Minner, S., A. Krohn, L. Burkhardt, et al. "Chromosomal deletions, tumor phenotype, and prognosis in prostate cancer." Journal of Clinical Oncology 29, no. 7_suppl (2011): 37. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.37.

Full text

Abstract:

37 Background: Chromosomal deletions are frequent in prostate cancer (PCa) but target genes and potential clinical significance are often unknown. This project aimed at the identification of frequent and new deletions in PCa and to study their association with tumor phenotype and PSA recurrence. Methods: Array CGH was performed on 77 advanced PCa. Deletions of interest were subsequently analyzed on a tissue microarray containing more than 2000 PCa with clinical follow-up data using fluorescence in situ hybridization (FISH). The FISH probes used included a break-apart probe for TMPRSS2-ERG and

APA, Harvard, Vancouver, ISO, and other styles

3

Yoshimoto, M., A. M. Joshua, S. Chilton-Macneill, et al. "Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer." Journal of Clinical Oncology 24, no. 18_suppl (2006): 10029. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10029.

Full text

Abstract:

10029 Background: Most of the early successes in identifying chromosomal translocations in neoplasias came from the study of hematological malignancies and sarcomas, with limited evidence that consistent genomic rearrangements were present in epithelial malignancies. Recently it was reported that ∼75% of prostate cancers carry a genomic rearrangement leading to fusion of the TMPRSS2 locus to either the ERG or ETV1 genes (both ETS transcription factors). In the fusion gene, the androgen-sensitive promoter elements of TMPRSS2 are thought to mediate over-expression of these ETS transcription fact

APA, Harvard, Vancouver, ISO, and other styles

4

Lara, Primo N., Andreas M. Heilmann, Julia A. Elvin, et al. "TMPRSS2-ERG Fusions Unexpectedly Identified in Men Initially Diagnosed With Nonprostatic Malignancies." JCO Precision Oncology, no. 1 (November 2017): 1–6. http://dx.doi.org/10.1200/po.17.00065.

Full text

Abstract:

Purpose TMPRSS2-ERG gene fusions are frequently found in prostate cancer and are pathognomonic for prostatic origin. In a series of cancer cases assayed with comprehensive genomic profiling (CGP) in the course of clinical care, we reviewed the frequency of TMPRSS2-ERG fusions in patient tumors of various histologic subtypes. Methods Frequency of TMPRSS2-ERG fusions was determined in CGPs from 64,263 cancer cases submitted to Foundation Medicine to assess genomic alterations suggesting benefit from targeted therapy. Genomic results are presented from an index case of prostate cancer that underw

APA, Harvard, Vancouver, ISO, and other styles

5

Mani, Ram-Shankar, Scott A. Tomlins, Kaitlin Callahan, et al. "Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer." Science 326, no. 5957 (2009): 1230. http://dx.doi.org/10.1126/science.1178124.

Full text

Abstract:

Gene fusions play a critical role in cancer progression. The mechanisms underlying their genesis and cell type specificity are not well understood. About 50% of human prostate cancers display a gene fusion involving the 5′ untranslated region of TMPRSS2, an androgen-regulated gene, and the protein-coding sequences of ERG, which encodes an erythroblast transformation–specific (ETS) transcription factor. By studying human prostate cancer cells with fluorescence in situ hybridization, we show that androgen signaling induces proximity of the TMPRSS2 and ERG genomic loci, both located on chromosome

APA, Harvard, Vancouver, ISO, and other styles

6

Dal Pra, Alan, Fiona Warde, Adrian Shea Ishkanian, et al. "TMPRSS2-ERG status and biochemical recurrence following radiotherapy for intermediate-risk prostate cancer." Journal of Clinical Oncology 30, no. 5_suppl (2012): 11. http://dx.doi.org/10.1200/jco.2012.30.5_suppl.11.

Full text

Abstract:

11 Background: Approximately 50% of prostate cancers (PC) contain TMPRSS2-ERG gene fusions leading to ERG overexpression. Pre-clinical data suggest that these fusions are due to altered DNA double-strand break repair status which could have therapeutic ramification for the use of radiotherapy (RT) and PARP inhibitors. The aim of this study was to correlate TMPRSS2-ERG status to biochemical failure following clinical induction of DNA breaks in the form of image-guided radiotherapy (IGRT) in intermediate-risk PC. Methods: Pre-treatment biopsies from two separate cohorts of intermediate-risk PC p

APA, Harvard, Vancouver, ISO, and other styles

7

Sung, Ji-Youn, Hwang Gyun Jeon, Byong Chang Jeong, et al. "Correlation of ERG immunohistochemistry with molecular detection of TMPRSS2-ERG gene fusion." Journal of Clinical Pathology 69, no. 7 (2015): 586–92. http://dx.doi.org/10.1136/jclinpath-2015-203314.

Full text

Abstract:

AimsTMPRSS2/E26 transformation-specific (ETS) family gene fusion in prostate carcinoma (PCa) can be detected by several methods including immunohistochemistry (IHC) for ETS-related gene (ERG), the diagnostic utility of which has not been clearly defined.MethodsWe explored TMPRSS2-ERG gene rearrangement status in 132 patients with PCa with four detection methods including fluorescence in situ hybridisation for TMPRSS2-ERG fusion, real-time reverse transcription PCR (RT-qPCR) for ERG and TMPRSS-ERG fusion transcript mRNA and IHC for ERG.ResultsConcordant results were found in 126 cases for the f

APA, Harvard, Vancouver, ISO, and other styles

8

Graff, Rebecca E., Allison Meisner, Thomas Ahearn, et al. "Pre-diagnostic circulating sex hormone levels and risk of prostate cancer by TMPRSS2:ERG status." Journal of Clinical Oncology 34, no. 2_suppl (2016): 93. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.93.

Full text

Abstract:

93 Background: Experimental studies have shown that androgen receptor stimulation can facilitate formation of the TMPRSS2:ERG gene fusion in prostate cell lines. No study has tested whether higher pre-diagnostic circulating sex hormone levels in men increase the risk of developing TMPRSS2:ERG positive prostate cancer specifically. Methods: We conducted a nested case-control study of 200 prostate cancer cases and 1,057 controls from the Physicians’ Health Study and Health Professionals Follow-up Study. We examined associations between pre-diagnostic circulating levels of total testosterone, fre

APA, Harvard, Vancouver, ISO, and other styles

9

KULDA, VLASTIMIL, ONDREJ TOPOLCAN, RADEK KUCERA, et al. "Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer." Anticancer Research 36, no. 9 (2016): 4787–94. http://dx.doi.org/10.21873/anticanres.11037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Knuuttila, Matias, Arfa Mehmood, Jenni Mäki-Jouppila, et al. "Intratumoral androgen levels are linked to TMPRSS2-ERG fusion in prostate cancer." Endocrine-Related Cancer 25, no. 9 (2018): 807–19. http://dx.doi.org/10.1530/erc-18-0148.

Full text

Abstract:

Intratumoral androgen biosynthesis is one of the mechanisms involved in the progression of prostate cancer, and an important target for novel prostate cancer therapies. Using gas chromatography-tandem mass spectrometry and genome-wide RNA sequencing, we have analyzed androgen concentrations and androgen-regulated gene expression in cancerous and morphologically benign prostate tissue specimens and serum samples obtained from 48 primary prostate cancer patients. Intratumoral dihydrotestosterone (DHT) concentrations were significantly higher in the cancerous tissues compared to benign prostate (

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "TMPRSS2-ERG fusion"

1

Coll, Bastus Nuria. "Study of the mechanisms causing the TMPRSS2:ERG gene fusion in prostate cancer." Thesis, Queen Mary, University of London, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.610967.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Souza, Bruna Ferreira de. "Investigação dos mRNAs de Fusão do Gene TMPRSS2/ERG em Pacientes com Câncer de Próstata." Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/17/17135/tde-11062013-165125/.

Full text

Abstract:

O interesse científico em rearranjos gênicos relacionados com a etiogênese e progressão do câncer relaciona-se, principalmente, à descoberta da fusão BCR/ABL na Leucemia Mieloide Crônica, sendo que desde então, houve uma evolução no manejo dessa doença, instigando uma série de estudos correlatos em outras neoplasias. Essas pesquisas culminaram no encontro do primeiro rearranjo gênico em tumores sólidos, o gene de fusão TMPRSS2/ERG, envolvendo a região promotora do gene da serina protease, o TMPRSS2, e o gene da família de fatores de transcrição ETS, o ERG. Ele é específico de adenocarci

APA, Harvard, Vancouver, ISO, and other styles

3

Delliaux, Carine. "Rôle du gène de fusion TMPRSS2.ERG dans la formation des métastases osseuses du cancer de la prostate." Thesis, Lille 2, 2017. http://www.theses.fr/2017LIL2S009/document.

Full text

Abstract:

Les tumeurs locales de la prostate sont associées à une évolution lente et une bonne survie, alors que les stades plus avancés révèlent dans 80% des cas des métastases osseuses incurables. La découverte de gènes de fusion issus de remaniements chromosomiques, tel que TMPRSS2:ERG dans plus de 50% des cas, a ouvert une nouvelle voie dans la compréhension du processus de cancérisation de la prostate. La présence de ce gène de fusion peut être associée à un mauvais pronostic dans de nombreuses études cliniques. Cependant, son rôle précis au cours de la cancérisation et de la progression du cancer

APA, Harvard, Vancouver, ISO, and other styles

4

Rinckleb, Antje [Verfasser]. "Common germline variants for prostate cancer risk: implication in DNA repair and TMPRSS2-ERG fusion formation / Antje Rinckleb." Ulm : Universität Ulm. Medizinische Fakultät, 2014. http://d-nb.info/1054996709/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Ovtcharov, Slav. "Impact of TMPRSS2-ERG fusion gene on prostate cancer cell response to chemotherapy, radiotherapy and androgen deprivation therapy." Thesis, University of Oxford, 2015. http://ora.ox.ac.uk/objects/uuid:f30bf48d-fff5-49e7-8258-107a500c8752.

Full text

Abstract:

Many aspects of the mechanisms by which prostate cancer (PCa) progresses from being a confined tumour to advanced metastatic and castration-resistant disease remain unclear. The aim of this study is to evaluate in vitro the potential role of the fusion gene TMPRSS2-ERG in the response of PCa cells to ionising radiation (IR) and androgen deprivation therapy (ADT). This research focused on assessing the presence of the TMPRSS2-ERG transcript across various PCa cell lines and identifying any correlation between the TMPRSS2-ERG transcript and other genes, particularly genes related to DNA damage r

APA, Harvard, Vancouver, ISO, and other styles

6

Tian, Tian. "Etudes fonctionnelles du gène de fusion TMPRSS2 : ERG dans le cancer de la prostate et les métastases osseuses associées." Thesis, Lille 2, 2013. http://www.theses.fr/2013LIL2S004.

Full text

Abstract:

Issu de remaniements chromosomiques, le gène de fusion TMPRSS2 :ERG a été identifié dans plus de 50% des cas des cancers de la prostate (CaP). Cette découverte a ouvert une nouvelle voie dans la compréhension du processus de cancérisation. De nombreuses études cliniques démontrent l’association de la présence de ce gène de fusion avec un mauvais pronostic. Erg (Ets-Related-Gene) est un facteur de transcription dont l’expression est associée, en particulier, à la mise en place du cartilage et plus largement du squelette. Une étude transcriptomique, comparant les transcriptomes des chondrocytes

APA, Harvard, Vancouver, ISO, and other styles

7

Broadhurst, Jessica. "A novel mechanism underlying prostate cancer progression : an investigation into the impact of insulin like growth factors (IGFs), PTEN and IGFBP2 on TMPRSS2:ERG fusion induction." Thesis, University of Bristol, 2014. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.701807.

Full text

Abstract:

Prostate cancer (PC) is the most commonly diagnosed male cancer in the UK. The transmembrane protease serine 2 (TMPRSS2) gene has been found fused to the ETS related gene (ERG), which codes for an oncogenic transcription factor in 50% of PC cases. Fusion puts the coding sequence of ERG under the control of the androgen regulated promoter and enhancer of TMPRSS2, resulting in androgen regulated ERG expression. Androgen is present at high concentrations in the prostate and therefore drives high levels of ERG production, resulting in increase proliferation, metastasis and invasion. Several studie

APA, Harvard, Vancouver, ISO, and other styles

8

Turpin, Anthony. "Étude des gènes réprimés par le récepteur aux androgènes dans les cancers de la prostate résistants à la castration et leur évolution neuroendocrine." Thesis, Lille, 2021. http://www.theses.fr/2021LILUS012.

Full text

Abstract:

Dans le cancer de la prostate, la présence de gènes de fusion, issus de remaniementschromosomiques TMPRSS2:ERG dans plus de 50% des cas, aboutit à une dérégulation dutranscriptome prostatique. Le récepteur aux androgènes (AR), membre de la famille desrécepteurs nucléaires, reste toutefois l’acteur majeur de l’évolution du cancer de la prostate.Notre objectif est d’identifier des gènes pouvant avoir un rôle dans l’évolution du cancerde la prostate, en lien avec la fusion TMPRSS2:ERG et AR.Par une analyse transcriptomique, à partir d’un modèle de surexpression de la fusionTMPRSS2:ERG dans une li

APA, Harvard, Vancouver, ISO, and other styles

9

De, Muga Salleras Silvia. "Estudi dels gens FGFR3, EGFR, PTEN, CXCR4 i del gen de fusió TMPRSS2-ERG en càncer de pròstata." Doctoral thesis, Universitat Autònoma de Barcelona, 2012. http://hdl.handle.net/10803/96816.

Full text

Abstract:

El càncer de pròstata és el tumor maligne no cutani més freqüent i una de les principals causes de mort per càncer en la població masculina. Tot i així, són menys els estudis moleculars realitzats sobre aquest tipus de càncer que en altres càncers (www.ncbi.nih.gov). L’objectiu de la tesi ha estat estudiar quins mecanismes moleculars estan implicats en la iniciació i progressió del càncer de pròstata. En el primer treball es va analitzar la freqüència de mutacions del gen FGFR3 ja que havien estat descrites mutacions d’aquest gen en altres tumors humans, però no en càncer de pròstata. Tamb

APA, Harvard, Vancouver, ISO, and other styles

10

Nottelmann, Mariné Andrea [Verfasser]. "Functional relevance of the candidate genes MSMB, NCOA4, TIMM23 and PARG in the prostate cancer risk region 10q11 for the emergence of oncogenic TMPRSS2:ERG fusions / Andrea Nottelmann Mariné." Ulm : Universität Ulm, 2016. http://d-nb.info/1110969481/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "TMPRSS2-ERG fusion"

1

Alves, Ines Teles, Jan Trapman, and Guido Jenster. Molecular biology of prostate cancer. Edited by James W. F. Catto. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199659579.003.0059.

Full text

Abstract:

Prostate cancer is a heterogeneous disease that arises through the acquisition of key malignant hallmarks. At the molecular level, prostate tumours are dependent upon the androgen receptor pathway, which affects cell function, growth, and behaviour through downstream androgen-regulated genes. Prostate cancer requires this activity and manipulates the AR pathway to maintain signalling. For example, mutation of the AR (to bind ligands other than androgens) or amplification/duplication of the AR allows signalling to continue in the absence of testosterone. Around 50% of prostate cancers have a ge

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "TMPRSS2-ERG fusion"

1

Wang, Jianghua, Michael Ittmann, and Yi Cai. "TMPRSS2/ERG Fusions." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2011. http://dx.doi.org/10.1007/978-3-642-16483-5_5839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Wang, Jianghua, Yi Cai, and Michael Ittmann. "TMPRSS2/ERG Fusions." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27841-9_5839-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Wang, Jianghua, Yi Cai, and Michael Ittmann. "TMPRSS2/ERG Fusions." In Encyclopedia of Cancer. Springer Berlin Heidelberg, 2017. http://dx.doi.org/10.1007/978-3-662-46875-3_5839.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Rathinavelu, Appu, and Arkene Levy. "Key Genes in Prostate Cancer Progression: Role of MDM2, PTEN, and TMPRSS2-ERG Fusions." In Prostate Cancer - Leading-edge Diagnostic Procedures and Treatments. InTech, 2016. http://dx.doi.org/10.5772/64337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "TMPRSS2-ERG fusion"

1

Delliaux, Carine, Tian V. Tian, Mathilde Bouchet, et al. "Abstract 1691: TMPRSS2:ERG fusion enhances osteoblastic phenotype of prostate cancer bone metastases." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1691.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ahearn, Thomas, Rebecca E. Graff, Andreas Pettersson, et al. "Abstract 1763: Body size and incidence of TMPRSS2:ERG fusion-positive and fusion-negative prostate cancer." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-1763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Graff, Rebecca E., Azra H. Ligon, Catherine Suppan, et al. "Abstract A29: The TMPRSS2:ERG gene fusion, ERG expression and prostate cancer outcomes: A cohort study and meta-analysis." In Abstracts: AACR International Conference on Frontiers in Cancer Prevention Research‐‐ Oct 22-25, 2011; Boston, MA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1940-6207.prev-11-a29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Yamoah, Kosj, Shivanshu Awasthi, Priti Lal, et al. "Abstract 1568: Clinical implications of tmprss2-erg fusion and tumor location in prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.am2019-1568.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Yamoah, Kosj, Shivanshu Awasthi, Priti Lal, et al. "Abstract 1568: Clinical implications of tmprss2-erg fusion and tumor location in prostate cancer." In Proceedings: AACR Annual Meeting 2019; March 29-April 3, 2019; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-1568.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Almami, Amal A. "Abstract 1686: Identification of potential prostate cancer biomarkers associated with TMPRSS2-ERG fusion and PTEN deletions." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-1686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Bhasin, Manoj, Bin Lu, and M. Simo Arredouani. "Abstract A31: Human prostate cancer transcriptome reveals distinct signaling pathway dysregulations associated with TMPRSS2:ERG fusion." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Nov 15-19, 2009; Boston, MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/1535-7163.targ-09-a31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Zammarchi, Francesca, George Boutsalis, William Gerald, and Luca Cartegni. "Abstract A70: Oncogenic potential of multiple splicing isoforms of the prostate‐cancer specific TMPRSS2‐ERG gene fusion product." In Abstracts: First AACR International Conference on Frontiers in Basic Cancer Research--Oct 8–11, 2009; Boston MA. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.fbcr09-a70.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Minner, Sarah Jane Pauline, Hueseyin Sirma, Ronald Simon, et al. "Abstract 3809: TMPRSS2-ERG gene fusion is strongly associated with elevated androgen receptor expression in early prostate cancer." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3809.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Bastus, Nuria Coll, Yong-Jie Lu, Lara K. Boyd, et al. "Abstract 3048: Enhanced androgen signalling pathway increases the risk of prostate cancer through induction of TMPRSS2:ERG fusion." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3048.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "TMPRSS2-ERG fusion"

1

Wang, Jianghua. Biological Effects of TMPRSS2/ERG Fusion Isoforms in Human Prostate Cancer. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada499922.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Ozpolat, Bulent, and Michael Ittmann. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene in Prostate Cancer Using Liposomal Nanotechnology. Defense Technical Information Center, 2013. http://dx.doi.org/10.21236/ada585108.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Ozpolat, Bulent, and Michael Ittmann. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene in Prostate Cancer Using Liposomal Nanotechnology. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada549160.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ozpolat, Bulent, and Michael Ittmann. Highly Specific Targeting of the TMPRSS2/ERG Fusion Gene In Prostate Cancer Using Liposomal Nanotechnology. Defense Technical Information Center, 2011. http://dx.doi.org/10.21236/ada549484.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Litovchick, Larisa. Functional Characterization of the Protein Product of the Prostate Carcinoma Gene Fusion TMPRSS2:ERG Using the Proteomic and Microarray Analyses. Defense Technical Information Center, 2009. http://dx.doi.org/10.21236/ada509751.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!